OCT 09 2009 PTO/SB/08 (2/92) Sheet 1 of 1 THE THE MAN Attorney's Docket No. Application Serial No. Form PTO-1449 10/579,088 ÁRR-0036 Applicant(s) INFORMATION DISCLOSURE STATEMENT Manzer Durrani, et al.

Filing Date: **Group Art Unit:** 1646 (use several sheets if necessary)

(use several sheets if necessary)				January 14, 2008			
				U.S. PATENT DOCUMENTS			
Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date (if appropriate)
	1.	06/1988	4,752,576	Brake, et al.			
	2.	10/1988	4,775,622	Hitzeman, et al.,			
•	3.	06/1989	4,837,148	Cregg			
	4.	06/1989	4,839,283	Kawasaki, et al.,			
	5.	05/1990	4,929,555	Cregg, et al.			
··	6.	07/1990	4,940,661	Etcheverry, et al.			
	7.	04/1991	5,010,003	Chang, et al.			
	8.	05/1991	5,013,652	Stausberg, et al.			
	9.	07/1999	5,922,569	Heim, et al.			
	10.	05/2000	6,068,994	Barr			
	11.	08/2000	6,103,500	Innis, et al.			
	12.	03/2001	6,204,012	Hellmuth, et al.			
	13.	5/19/2002	5,114,953	Galardy, et al.			
	14.	6/30/1998	5,773,438	Levy, et al.			
	15.	12/9/1997	5,696,147	Galardy			
	16.	4/6/1999	5,892,112	Levy, et al.			
	17.		6,544,497	Zhu, et al.			
	′18.	02/17/2004	6,693,096	Fritz, et al.			
Exam.	19.	5/25/2004	6,740,655	Magee, et al.			
Initros	20.	10/26/1999	5,972,986	Seibert, et al.			
	21.	10/22/2002	6,469,040	Seibert, et al.			
	22.		6,133,304	Peterson, Jr., et al.			
	23.	07/14/1998	5,780,440	Lezdey, et al.			
	24.	10/26/1993	5,256,657	Singh, et al.			
	25.	04/10/2003	2003/0068280	Bannister, et al.			
		11/13/2003	2003/0211548	Packard, et al.			
	27.	07/25/2002	2002/0099013	Piccariello, et al.			
	28.	1/14/1997	5,594,106	Black, et al.			
	29.	04/24/2003	2003/0078276	Andrianjara, et al.			
	30.	04/17/2003	2003/0073217 A1	Barr, et al.			
	31.		4,752,576	Brake, et al.			
	32.		6,489,308 B1	Shapiro, et al.			
	33.		5,993,783	Eljamal, et al.			
	<u> </u>		· · · · ·				
			· · · · · · · · · · · · · · · · · · ·				
1 1	1.	<u></u>	1			Ť T	

EXAMINER:	DATE CONSIDERED:
EXAMINEIX.	DATE CONSIDERED.

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

*If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identical in the statement and relied upon for an earlier filing date under 35 U.S.C. §120. 37 C.F.R. §1.98 (d).

Form PTO-1449			49	Attorney's Docket No. ARR-0036	Application Serial No. 10/579,088			
INICO	DRAKTIO	N DISCLOSU	DE STATEMENT	Applicant(s)	10/5	77 3,000		
INFO	RIVIATIO	N DISCLOSU	RE STATEMENT	Manzer Durrani, et al.				
				Wallzer Du	ıııaııı, c	t ui.		
		· · · · · · · · · · · · · · · · · · ·		Filing Date:	Gro	up Art Unit:		
	(use sev	eral sheets if	necessary)	January 14, 2008	164			
	<u> </u>			EIGN PATENT DOCUMENTS			·	
Examiner	Ref.	Date	Document No.	Name .	Class	Subclass	Transla	tion
Initials	No.					Į.	YES	NO
	34.	11/22/1984	WO 1984/04538	WO				
	35.	06/27/2002	WO 2002/50287	WO				
	36.	12/27/1990	EP 73,654 A	EP				
· ; ; ; .	37.	09/28/1988	EP 0 284 044 A1	EP				
1.2	38.	06/27/2002	WO 02/50287	WO				
1. 0	39.	10/17/1996	WO 96/32152	WO				
	40.	04/23/1998	WO 98/16205	WO				
	41.	09/21/2000	WO 00/54797	WO				
	42.	07/22/2004	WO 2004/060528	WO				
	43.	07/31/2002	EP 0 648 838	EP				
	44.	10/02/2002	EP 1 047 450	EP				
	45.	07/31/2002	EP 1 226 136	EP		.]		
	46.	06/15/2000	WO 00/34237	WO				
	47.	07/11/2002	WO 02/053138	WO				
	48.	08/22/2002	WO 02/064080	WO				
	49.	08/21/2003	WO 03/068188	WO			•	
	50.	09/18/2003	WO 03/075959	WO				
	:51.	07/01/1999	WO 2004/103364	_WO				
	52.	01/13/2005	WO 2005/003150	WO				
	53.	06/11/1992	WO 92/09282	WO				
	54.	06/11/1992	WO 92/09556	WO			***	
	55.	06/11/1992	WO 92/09563	WO				
	56.	07/22/1993	WO 93/13741	WO				
- 75	57.	02/03/1994	WO 94/02446	WO				
	58.	09/29/1994	WO 94/21625	WO			·	
11		10/13/1994	WO 94/22309	WO				
		04/13/1995	WO 95/09841	WO				
		07/27/1995	WO 95/19965	WO			•	
	62.		WO 96/16027	WO				
		11/13/1997	WO 97/42168	WO		† <u>†</u>		
		2/26/1998	WO 98/07742	WO				
		04/09/1997	WO 98/14424	WO			· · · · · · · · · · · · · · · · · ·	
		10/8/1998	WO 98/43946	WO	·			
	67.		WO 98/47863	WO	·····		•	
	68.		WO 99/44989	WO		 		
		07/01/1999	WO 99/32150	WO		1 7.00		
EYAMINE				DATE CONSIDERED:		<u> </u>	· · · · · · ·	

EXAMINER:	DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not inconformance and not considered. Include a copy of this form with next communication to applicant.

*If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identical in the statement and relied upon for an earlier filing date under 35 U.S.C. §120. 37 C.F.R. §1.98 (d).

			149	Attorney's Docket No.	Application Serial No.	
INICO	DIATIO	I DICCI ACIII		ARR-0036 Applicant(s)	10/579,088	
INFORMATION DISCLOSURE STATEMENT			KE STATEWENT	Manzer Durrani, et al.		
				manzer bu	Train, or al.	
				Filing Date:	Group Art Unit:	
		eral sheets if		January 14, 2008	1646	
	70.	07/31/2002	EP 1 226 119	EP		
			(including a	OTHER DOCUMENTS uthor, title, date, pertinent pages, etc.)		
Examiner	Ref.	Title	(mora amig a	auto, inter date, per interit pages, etc.,		
Initials	No.		· -			
	71.			in Yeast," The Journal of Biological Chemis		
	72.	Technology,	" 29: 611-620, 2001.	overy of Recombinant Protease Inhibitor Alp	•	
	73.	Russell, et a 258(4): 2674-		ce of the Yeast Alcohol Dehyorgenase II Gen	e," The Journal of Biological Chemistry,	
	74.	Barr, et al., "	Yeast Genetic Enginee	ring," Chap. 6, Butterworths, 1989.		
	75.	Broach, et al., "Transformation in Yeast: Development of a Hybrid Cloning Vector and Isolation of the CAN1 Gene," Gene, <u>8</u> :121-133, 1979.				
э ^й	76.	Pearson, et al., "Improved Tools for Biological Sequence Comparison," Proceedings of the National Academy of Science, 85: 244-2448, 1988.				
	77.		et al., "Regulated High l aal, <u>1(5)</u> : 603-608, 1982.	Efficiency Expression of Human Interferon-A	lpha in Saccharomyces cerevisiae," The	
	78.	Kurachi, K., et al., "Cloning and Sequence ofcDNA Coding for α₁-Antitrypsin," Proc Natl Acad Sci USA, Biochemistry, 78(11): 6826-6830, 1981.				
	79.		t al., "Structure of a Yea ature α-Factor," Cell, <u>30</u>	ast Pheromone Gene (MF αι): A Putative α-Fa 2: 933-943, 1982.	actor Precursor Contains Four Tandem	
 	80.	Zakian, V.A., et al., "Construction, Replication, and Chromatin Structure of TRP1 R1 Circle, a Multiple-Copy Synthetic Plasmid Derived from Saccharomyces cerevisiae Chromosomal DNA", Molecular and Cellular Biology, 2(3): 221-232, 1982.				
	04			nary Change in Proteins," Atlas of Protein S	equence and Structure, National	
	81.	biomedical r	Research Foundation, <u>{</u>	<u>43)</u> :343-338, 1979.		
	82.	Hein, J "Un	ified Approach to Aligr	ment and Phylogenies," Methods in Enzymo	ology, <u>183</u> : 626-645, 1990.	
	83.		., et al., "Fast and Sens tions, <u>5(2)</u> : 151-153, 198	itive Multiple Sequence Alignments on a Mic 9.	crocomputer," CABIOS	
	84.	Jones, E.W.,	"Vacuolar Proteases in	n Yeast Saccharomyces Cerevisiae," Method	s in Enzymology, 85(31):372-386, 1990.	
	85.		et al., "Integrative Tran Biology, <u>6(1)</u> : 142-149,	sformation of Candida albicans, Using a Clor 1986.	ned Candida ADE2 Gene," Molecular	
EXAMINER				DATE CONSIDERED:		

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in
conformance and not considered. Include a copy of this form with next communication to applicant.
*If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the
PTO in a prior application that is identical in the statement and relied upon for an earlier filing date under 35 U.S.C. §120. 37 C.F.R. §1.98 (d).

	-	Form PTO-1449	Attorney's Docket No. ARR-0036	Application Serial No. 10/579,088		
	INFORMATIO	N DISCLOSURE STATEMENT	Applicant(s)	10:013,000		
			Manzer Durrani, et al.			
	(400,004	eral abouts if necessary	Filing Date:	Group Art Unit: 1646		
	(use seve	eral sheets if necessary) Kunze et al. "Transformation of the	January 14, 2008	ndida maltosa and Pichia guilliermondii," Journal		
	86.	of Basic Microbiology, <u>25(2)</u> : 141-14				
	87.	Myers, E.W., et al. "Optimal Alignme				
	88.	Robinson, D.F., "Comparison of Lai 119,1971.	beled Trees with Valency Three," J	ournal of Combinational Theory, <u>11</u> : 105-		
	89.	Saitou, N., et al., "The Neighbor-Joi Biology and Evolution, pp. 406-425,		constructing Phylogenetic Trees," Molecular		
	90.	Wilbur, W.J., et al., "Rapid Similarity 726-730, 1983.	y Searches of Nucliec Acid and Pro	tein Data Banks," Proc Natl Acad of Sci USA, <u>80</u> :		
	91.	Zou, et al., "Maspin, a Serpin with Tumor-Suppressing Activity in Human Mamary Epithelial Cells," Science, <u>263</u> : 526-529, 1994.				
	92.	Gleeson, M.A., et al., "Transformation of the Methylotrophic Yeast Hansenula polymorpha," Journal of General Microbiology, 132: 3459-3465, 1986.				
	93.	Roggenkamp, R., et al., "Transformation of the Methylotrophic Yeast Hansenula polymorpha by Autonomous Replication and Integration Vectors," Mol. Gen. Genet., <u>202:</u> 302-308, 1986.				
	94.	Das, et al., "Transformation of Kluyveromyces Fragilis," Journal of Bacteriology, <u>158(3)</u> : 1165-1167, 1984.				
	95.	De Louvencourt, et al., "Transformation of Kluyveromyces lactic by Killer Plasmid DNA," Journal of Bacteriology, 154(2): 737-742, 1983.				
	96.	Van Den Berg, et al., "Kluyveromyces as a Host of Herterologous Gene Expression: Expression and Secretion of Prochymosin", Biotechnology, 8: 135-140, 1990.				
	97.	Cregg, et al., "Pichia Pastoris as a Host System for Transformations," Molecular and Cellular Biology, <u>5(12)</u> : 3376-3385 1985.				
	98.	Hinnen, A., et al., "Transformation of Yeast," Proc. Natl. Acad of Sci. USA, Genetics, 75(4): 1929-1933, 1978.				
	99.	Ito, H., et al., "Transformation of Intact Yeast Cells Treated with Alkali Cations", Journal of Bacteriology, 153(1): 163-168, 1983.				
	100.	Davidow, L.S., et al., " Integrative Tr	ansformation of the Yeast Yarrowi	a lipolytica," Current Genetics, <u>10</u> : 39-48, 1985.		
	101.	_	<u> </u>	lytica," Current Genetics, <u>10</u> : 49-58, 1985.		
	102.	Winkler, M., "Time-Profiling and Env	viromental Design in Computer -Co	ntrolled Fermentation and Enzyme Production,"		
EX	AMINER:		DATE CONSIDERED):		

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in

*If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identical in the statement and relied upon for an earlier filing date under 35 U.S.C. §120. 37 C.F.R. §1.98 (d).

conformance and not considered. Include a copy of this form with next communication to applicant.

LIBC/3689098.1	123887-182052

Form PTO-1449			Attorney's Docket No.	Application Serial No.	
INEC	DMATIO	N DISCLOSURE STATEMENT	ARR-0036 Applicant(s)	10/579,088	
INFO		1 DISCLOSURE STATEMENT	Manzer Durn	ani, et al.	
			Filing Date:	Group Art Unit:	
	(use seve	eral sheets if necessary)	January 14, 2008	1646	
		96-184, 1991.	Enzymes from Yeast: Production Control, El	lis Horwood Limited, Chp. 4 and 5, pp.	
	103.	Schiestl, et al., "High Efficiency Transformation of Intact Yeast Cells Using Single Stranded Nucleic Acids as a Carrie Current Genetics, 16: 339-346, 1989.			
	104.	Jones, E.W., "Tackling the Protease Problem in Saccharomyces Cerevisiae," Methods in Enzymology, <u>194</u> : 428-453, 1991.			
:	105.	du Preez, J.C., et al., "Transcriptional Repression of ADH2-Regulated β-xylanase Production by Ethanol in Recombinant Strains of Saccharomyces Cerevisiae," FEMS Yeast Research, 1: 233-240, 2001.			
	106.	European Search Report dated Janua	ry 9, 2007.		
	Kaslow, D.C., et al., "Production, Purification and Immunogenicity of a Malaria Transmission-Blocking Vaccine 107. Candidate: TBV25H Expressed in Yeast and Purified Using Nickel-NTA Agarose," Nature Publishing Group, 12: 1994.				
	108.	Noronha, S.B., et al., "Transition Phase in the Production of Recombinant Proteins in Yeast Under the ADH2 Promoter: An Important Step for Reproducible Manufacturing of a Malaria Transmission Blocking Vaccine Candidate," Journal of Individual Microbiology & Biotechnology, 20:192-199, 1998.			
	109.	O'Connor, G.M., "Design and Evaluation of Control Strategies for High Cell Density Fermentations," Biotechnology and Bioengineering, 39 (3):293-304, 1992.			
	110.	Sabin, E.A., et al., "High-Level Expression and in Vivo Processing of Chimeric Ubiquitin Fusion Proteins in Saccharomyces Cervisiae," Bio/Technology, 7: 705-709, 1989.			
	111.	Amiali, et al., "High Nisin Z Production by Lactococcus Lactis UL719 in Whey Permeate with Aeration," World Journa of Microbiology & Biotechnology, 14: 887-894, 1998.			
:	112.	Beatty, et al., "Kinetics of Association of Serine Proteinases with Native and Oxidized Alpha-1-Proteinase Inhibitor Alpha-1-Antichymotrypsin," J. Biol. Chem., 255(9): 3931-3934, 1980.			
	Vemuri, et al., "Stability and Characterization of Protein and Peptide Drugs: Case Histories," Wang and Pearlin Plenum Press, NY, Chap. 9 pp. 263-285, 1993.			Histories," Wang and Pearlman,	
	114.	Vemuri, S., et al., "Effect of Cryoprotectants on Freezing, Lyophilization, and Storage of Lyophilized Recombinar Alpha1-Antitrypsin Formulations," PDA Journal of Pharmaceutical Science and Technology, 48(5): 241-246, 1994			
	115.	Pomberton P. et al. "Inhaled recombinant Alpha 1 Antitrungin Ameliorates Cigarette Smoke Indused Emphysion			
	116.	Stockley et al. "Therapeutic Efficacy of Alpha-1 Antitrypsin (AAT) Augmentation Therapy on the Loss of Lung Tis			
	117.	2007.	for Emphysema: A Clinical Investigation,"		
	118.	<u>128(1)</u> : 199-203, 1985.	Ipha-One Antitrypsin and Microheterogeneit		
	119.	Schasteen, C.S., et al., "Synthetic Pep	tide Inhibitors of Complement Serine Protea	ses – Significant Increase in Inhibitor	
EXAMINE	₹:		DATE CONSIDERED:		

EXAMINER: Initial if citation considered, whether or not the citation conformance and not considered. Include a copy of this form with next c	
*If an asterisk is placed beside the reference number, a copy is not provid PTO in a prior application that is identical in the statement and relied upo	

			Attorney's Docket No. ARR-0036	Application Serial No. 10/579,088	
			Applicant(s) Manzer Duri	rani, et al.	
	(use seve	eral sheets if necessary)	Filing Date: January 14, 2008	Group Art Unit: 1646	
		479, 1991.	the Functional Equivalence Hypothesis," N		
	120.		ema," Current Opinion in Pulmonary Medic		
·	121.	Huang, et al., "Expression and Purifice Biotechology Prog, 17: 126-33, 2001.	ation of Functional Human Alpha1-Antitrype	sin from Cultured Plant Cells,"	
	122.	Rabe, "Outcome Measures in COPD, "	Primary Care Respiratory Journal, 13: 177-	178, 2004.	
	123.	Possengra et al. "Synthosis in Voset of a Eurotional Ovidation Registant Mutant of Human Alpha Antitornain." No			
	124.	Medicine, 21(4):621-632, 2000.	Pathogenesis of Chronic Obstructive Pulmo	•	
;: -	125.	Travis, et al., "Isolation and Properties of Recombinant DNA Produced Variants of Human Alpha1-Proteinase Inhib Journal of Biological Cheimstry, 260(7): 4384-4389, 1985.			
	126.	Terashima, et al., "Production of Functional Human Alpha1-Antitrypsin by Plant Cell Culture," Appl. Microbiol. Biotechnol., 52: 516-523, 1999.			
	Barnes, P.J., "Novel Approaches and Targets for Treatment of Chronic Obstructive Pulmonary Disease," <i>Am.J. Res. Crit. Care Med.</i> , 160:S72-S79, 1999.			· · · · · · · · · · · · · · · · · · ·	
	Roche, N., et al., "Current Issues in the Management of Chronic Obstructive Pulmonary Diseases," Respirology, 2: 2 229, 1997.				
	129.		f COPD," Current Pharmacogenomics, 1(4):		
Hubbard, R.C., et al., "Anti-Neutrophil-Elastase Defe 130. Deficiency Directly Augmented with an Aerosol of A 1989.					

EXAMINER:	DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

*If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identical in the statement and relied upon for an earlier filing date under 35 U.S.C. §120. 37 C.F.R. §1.98 (d).